1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Price Chart
4. Valuation
5. Offer Terms
6. Financial Statements
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
IMMX
Listed on
2021-12-16
Sector
Health Care
Subsector
Pharmaceuticals
Offer Price
$5.00
first filed $5.00–$6.00Shares Offered
4.2M
13.86M
$37.9M
30.3%
Implied Upside vs Midpoint
Description
We are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”)™ in oncology and inflammation. Our lead asset, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously), and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging our TME Normalization™ Technology, delivered deep into the tumor micro-environment (“TME”). Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific™ Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. As of the date of this prospectus, we have not generated any revenues. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our Company, business planning and raising capital. --- We were incorporated as a California limited liability company in 2012 and converted to a Delaware corporation in January 2014. In August 2016, we established a wholly-owned Australian subsidiary, Immix Biopharma Australia Pty Ltd., in order to conduct various pre-clinical and clinical activities for the development of our product candidates. Our principal executive offices are located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064 and our telephone number is (310) 651-8041. Our website address is www.immixbio.com.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
Net cash / market cap | 1.0% | 0.7% | ||
Debt / equity | 0.00 | 0.00 | ||
Current ratio | 0.10 | 0.27 | ||
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||
▼ Priced at $5.00, 9% below the midpoint of the first filed range ($5.00–$6.00, 2021-10-06).
Each filing is plotted ahead of the first trading day on the price chart.
| Filed | Form | Price range | Price | Shares offered | Deal size |
|---|---|---|---|---|---|
| 2021-10-06 | S-1/A | $5.00–$6.00 | — | 3,825,000 | $21.0M |
| 2021-10-15 | S-1/A | $5.00–$6.00 | — | 3,825,000 | $21.0M |
| 2021-10-28 | S-1/A | $5.00–$6.00 | — | 3,825,000 | $21.0M |
| 2021-11-04 | S-1/A | $5.00–$6.00 | — | 3,825,000 | $21.0M |
| 2021-12-17 | 424B4 | — | $5.00 | 4,200,000 | $21.0M |
Immix Biopharma, Inc. income statement and balance sheet, FY Dec 2022 to FY Dec 2025, as reported in SEC filings.
| Metric | FY Dec 2022after listing | FY Dec 2023after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Operating income | ($8.2M) | — | ($22.7M) | ($30.0M) |
| Net income | ($8.2M) | — | ($21.6M) | ($29.4M) |
| Metric | FY Dec 2022after listing | FY Dec 2023after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Total assets | $14.9M | — | $22.9M | $105M |
| Total liabilities | $1.7M | — | $9.7M | $11.0M |
| Total equity | $13.2M | $16.2M | $13.3M | $93.8M |
| Cash & equivalents | $13.4M | — | $17.7M | $93.9M |